Latest Mergers And Acquisitions News

Pilot Energy has made significant strides in Q4 2025 with the launch of a modular data centre joint venture, progress on a hybrid solar and battery project, and advancement of offshore gas exploration partnerships, supported by substantial new financing.

Blue Energy Limited reports steady progress on its Sapphire gas project and awaits key government decisions on additional resource areas, positioning itself strongly in Queensland's evolving energy landscape.

Vita Resources NL, formerly Bastion Minerals, has advanced its Canadian and Australian projects with new exploration agreements and acquisitions, supported by a recent capital raise. The company is gearing up for significant exploration activities in 2026 under its refreshed corporate identity.

Holista Colltech has reported a positive operating cash flow for the December quarter, driven by disciplined cost management and a successful capital raise, despite softer sales and ongoing legal disputes.

Opthea Limited has streamlined its operations with a NASDAQ delisting and completed a strategic review, positioning itself to advance the OPT-302 treatment for LAM with a robust cash position.

Emerald Resources NL reported solid December quarter gold production from its Okvau Gold Mine and significant resource upgrades at its Dingo Range and Memot projects, underpinning its growth trajectory.

MRG Metals has expanded its rare earth portfolio through the acquisition of the high-grade Garies Rare Earth Project in South Africa, while also progressing key projects in Mozambique, signalling a diversified growth strategy in critical minerals.

Nagambie Resources and Alkane Resources have entered a binding agreement for a joint venture that could see Alkane invest up to $27.5 million to earn an 80% stake in Nagambie's key mining tenements, leveraging Alkane’s existing processing infrastructure to accelerate production.

Paradigm Biopharmaceuticals reports solid progress in its Phase 3 knee osteoarthritis trial, expanding internationally and publishing key Phase 2 biomarker data. The company maintains a robust cash position to support ongoing clinical milestones.

PainChek has achieved FDA regulatory clearance enabling its device to qualify for US Remote Therapeutic Monitoring reimbursement, positioning the company for significant growth in the expanding US healthcare market. The company also reports strong global licence growth and a solid pipeline across multiple regions.

PainChek has secured FDA De Novo clearance, enabling entry into the vast US healthcare market with a $3 billion Remote Therapeutic Monitoring opportunity. The company reports $5.6 million contracted ARR and a strong global footprint in aged care.

PentaNet Ltd reported a positive net operating cash flow of A$710,000 for the December 2025 quarter, alongside a strong cash position of A$2.42 million. The company completed its final payment for a 15-year 5G spectrum license while maintaining access to substantial financing facilities.